OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Robson on the Application of Precision Medicine in Breast Cancer

January 17th 2020

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Dr. Tauer on the Expansion of Subtyping in Breast Cancer

January 17th 2020

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Dr. Wang on Precision Medicine in MCL

January 17th 2020

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

January 17th 2020

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Dr. Brown on the Success of Blinatumomab in the AALL 1331 Trial

January 17th 2020

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Dr. Schlumbrecht on Treatment in Uterine Leiomyosarcoma

January 17th 2020

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

Dr. Ferraro on the Use of Molecular Profiling in Pancreatic Cancer

January 17th 2020

Pablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.

Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

January 17th 2020

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

Dr. Fakhri on Tumor Lysis Syndrome Associated With Venetoclax/Obinutuzumab in CLL

January 16th 2020

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Dr. Chaudhry on Novel Treatment Regimens in Relapsed/Refractory Multiple Myeloma

January 16th 2020

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses novel treatment regimens in relapsed/refractory multiple myeloma.

Dr. Rule on the Next Steps for BTK Inhibitors in MCL

January 16th 2020

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Dr. Mesa on the Efficacy of Fedratinib in Patients With Myelofibrosis and Low Platelet Counts

January 16th 2020

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

January 16th 2020

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Dr. Schlumbrecht on Remaining Challenges in Uterine Leiomyosarcoma

January 16th 2020

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

Dr. Hussein on the Evolution of Treatment in HCC

January 16th 2020

Atif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.

Dr. Hays on Immunotherapy in Ovarian Cancer Treatment

January 15th 2020

John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

January 15th 2020

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.

Dr. Chittoor on Guidelines for Liquid Biopsies in NSCLC

January 15th 2020

Sreeni Chittoor, MD, FACP, discusses the FDA and National Comprehensive Cancer Network recommendations for use of liquid biopsies in patients with non–small cell lung cancer.

Dr. Mims on Developed Mutations in AML

January 15th 2020

Alice S. Mims, MD, discusses developed resistance in acute myeloid leukemia.

Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.